Urease-Powered Nanomotor Containing STING Agonist for Bladder Cancer Immunotherapy
발표자
()
초록
내용
Most non-muscle invasive bladder cancers have been treated by transurethral resection and following intravesical injection of immunotherapeutic agents. However, the delivery efficiency of therapeutic agents into bladder wall is low due to frequent urination, which leads to high recurrence rate and side effects, making it the most expensive cancer to treat worldwide. Here, we report a urease-powered nanomotor containing agonist of stimulator of interferon genes (STING@nanomotor) for efficient activation of immune cells in bladder wall. After characterization, we performed in vitro motion analysis and assessed in vivo swarming behaviors of nanomotors. The intravesical instillation resulted in the effective penetration and retention of nanomotors in the bladder. Finally, we confirmed the anti-tumor effect of STING@nanomotor, recruitment of CD8+ T cells and enhanced anti-tumoral immune response. Taken together, STING@nanomotor would provide a new paradigm as a next-generation platform for bladder cancer immunotherapy.